The content is produced solely by The Conversation. At least 40% of women experience hair loss or alopecia over their lifetimes. This could be alopecia areata (patchy hair loss), traction alopecia ...

The most common type of hair loss in women is androgenetic alopecia, or female pattern hair loss. Hair loss can be caused by genetics, stress, medications, or autoimmune conditions like alopecia ...

2 "Early onset alopecia areata can be more severe, leading to extensive hair ... when administered during pregnancy. Advise pregnant women and women of reproductive potential of the potential ...

Advise women not to breastfeed during treatment ... Baricitinib provides significant hair regrowth in adolescents with severe alopecia areata: 36-week efficacy and safety results from a Phase ...

Patients with severe to very severe alopecia areata saw hair regrowth with bempikibart treatment within 24 weeks. Hair regrowth seemed to persist after treatment cessation to week 36. ORLANDO ...

For adolescents with severe alopecia areata (AA), baricitinib is efficacious for hair regrowth, according to a study presented at the annual meeting of the American Academy of Dermatology ...

42.4% of adolescents with severe alopecia areata who received baricitinib had 80% or more scalp hair coverage after 36 weeks. An expert said it is the largest trial to date studying treatment in ...

Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg Patients treated with baricitinib 4 mg saw significant ...

2 "Early onset alopecia areata can be more severe, leading to extensive hair loss that frequently does not improve with topicals or corticosteroids often prescribed as first-line therapy," said ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study PR Newswire INDIANAPOLIS, March 8, 2025 Late-breaking results pr ...